Why Edgewise Therapeutics Stock Rocked the Market Today
Source: Motley Fool
2025-12-24 18:20:17 ET
Edgewise Therapeutics (NASDAQ: EWTX) had some rather good news to report from the lab, and investors welcomed it on Wednesday. On that considerable tailwind, the biotech 's share price surged nearly 26% higher on the last trading day before Christmas.
That morning, Edgewise presented interim data from its ongoing Phase 2 clinical trial of EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). This is a genetic heart condition in which the heart's muscle thickens, affecting its ability to pump blood throughout the body.
Image source: Getty Images.
Edgewise Therapeutics Inc.
NASDAQ: EWTX
EWTX Trading
15.75% G/L:
$39.055 Last:
2,691,761 Volume:
$40.60 Open:
EWTX Latest News
June 01, 2026 08:30:00 am
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
EWTX Stock Data
$3,280,862,770
54,628,112
N/A
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Boulder
